Loading…
Loading…
MMP (Magellan Midstream Partners, L.P.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MMP and 80,000+ other tickers.
See exactly how MMP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MMP and 80,000+ other tickers.
Magellan Midstream Partners, L.P. (MMP) is an energy infrastructure firm primarily engaged in the logistics of refined petroleum products and crude oil throughout the United States. The company's operations are divided into two principal business units: Refined Products and Crude Oil. Its Refined Products segment oversees an extensive pipeline system for transporting a variety of fuels, including gasoline, diesel fuel, aviation fuel, kerosene, and heating oil. This network serves a broad spectrum of clients, from wholesalers, retailers, and traders to major transportation providers like…
Pulmatrix Announces First Quarter 2026 Financial Results PR Newswire FRAMINGHAM, Mass., May 15, 2026
Equinor's Marketing, Midstream and Processing (MMP) division, which includes energy trading, will report a first-quarter adjusted operating profit that exceeds the company's $400 million guidance, the group said on Thursday.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel target for cancer treatment and demonstrate the positive properties of Bicycle® Radioconjugates (BRC®).
BOTOX® Cosmetic is the first neurotoxin approved in China for the treatment of masseter muscle prominence (MMP), the largest global market for MMP. Approval supported by well-established safety profile and robust clinical trials demonstrating BOTOX® Cosmetic is effective in reducing the prominence of the masseter muscle.
Dividend growth stocks often provide reliable cash flows and long-term wealth for income investors. Screening dividend stocks based on safety, growth, and consistency can be beneficial to find new opportunities important for investors. In this month's article, we highlight these five dividend stocks: Medifast, Realty Income, ONEOK, VICI Properties, and Cogent Communications Holdings.